Relmada Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full-Year 2020 Financial Results

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/24/2026

1. QCOM
2. CBRS
3. FDX
4. USO
5. MU
6. SPY
7. KBH
8. HTZ
9. HON
10. JPM

Go back to Relmada Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full-Year 2020 Financial Results

Relmada Therapeutics (RLMD) Misses Q4 EPS by 12c

March 23, 2021 4:24 PM EDT

Relmada Therapeutics (NASDAQ: RLMD) reported Q4 EPS of ($1.28), $0.12 worse than the analyst estimate of ($1.16).

"We have achieved significant progress in advancing our lead product candidate, REL-1017, which has the potential to be the first U.S. Food and Drug Administration (FDA)-approved anti-depressant for adjunctive treatment of major depressive disorder (MDD),"... More